Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Heather Manos

Addiction Medicine Charlotte, NC Medical Doctor

NPI 1427186022 CMS profile 944969

6010 E Wt Harris Blvd, Charlotte, NC 28215

Open in the dashboard

General payments

$2,501

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Manos of Charlotte, NC is reported in the CMS Open Payments database as having received $2,501 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $525 21
2024 General $367 17
2023 General $887 36
2022 General $291 16
2021 General $260 14
2020 General $135 2
2019 General $36 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Manos
  • Addiction Medicine median
  • Middle half of Addiction Medicine
  • National median

In program year 2025, general payments to Heather Manos were reported at $525. Among 306 Addiction Medicine profiles paid that year, the median was $147 and the middle half received between $46 and $381.

Show as a table
Year Heather Manos Addiction Medicine median Middle half National median
2019 $36 $96 $32–$265 $163
2020 $135 $53 $20–$176 $114
2021 $260 $86 $24–$265 $132
2022 $291 $89 $27–$330 $149
2023 $887 $102 $39–$363 $160
2024 $367 $110 $38–$311 $164
2025 $525 $147 $46–$381 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Indivior Inc. $331 15 payments
  2. ViiV Healthcare Company $179 7 payments
  3. Braeburn Inc. $159 3 payments
  4. AbbVie, Inc. $154 8 payments
  5. Alkermes, Inc. $149 6 payments
  6. Amgen Inc. $145 2 payments
  7. Gilead Sciences, Inc. $121 6 payments
  8. US WorldMeds, LLC $119 1 payment
  9. Uswm, LLC $107 6 payments
  10. Napo Pharmaceuticals Inc $90 5 payments
  11. Other $947 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,474 107 payments
  2. Education $27 1 payment
Products named General payments · program years 2019–2025
  1. SUBLOCADE $270 12 payments
  2. BRIXADI $159 3 payments
  3. VIVITROL $149 6 payments
  4. APRETUDE $140 4 payments
  5. Lucemyra Psychiatry/Psychology $119 1 payment
  6. Lucemyra Psychiatry/Psychology $107 6 payments
  7. ZIMHI $107 6 payments
  8. Mytesi $90 5 payments
  9. VRAYLAR Neuroscience $82 4 payments
  10. VRAYLAR Neuroscience $73 4 payments
  11. Other $1,330 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

292

Median for Family Practice: 1,826

Drug cost

$30,109

Median for Family Practice: $120,094

Branded share of claims

53.1%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 111 $16,819
Zubsolv Buprenorphine Hcl/Naloxone Hcl Brand 13 $5,818
Varenicline Tartrate Generic 13 $3,703
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 17 $1,239
Naltrexone Hcl Generic 14 $1,203
Duloxetine Hcl Generic 12 $286
Quetiapine Fumarate Generic 19 $275
Olanzapine Generic 12 $244
Gabapentin Generic 17 $240
Prazosin Hcl Generic 11 $115

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SUBLOCADE
  • Indivior Inc. $75
$75 — —
VIVITROL
  • Alkermes, Inc. $61
$61 — —
BRIXADI
  • Braeburn Inc. $48
$48 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $24
$24 — —
RYBELSUS
  • Novo Nordisk Inc $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record